EFTR eFFECTOR Therapeutics Inc
3,301
$2.14
$0.06
(2.88%)
| Watchers | 3,301 |
| 52-Wk Low | $1.60 |
| 52-Wk High | $37.00 |
| Market Cap | $10.07M |
| Volume | 148.00 |
| 52-Wk High | $37.00 |
| 52-Wk Low | $1.60 |
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung CancerGlobe Newswire • about 1 month ago
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
eFFECTOR Therapeutics (NASDAQ:EFTR - Get Free Report)s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on...
eFFECTOR Therapeutics (NASDAQ:EFTR Get Free Report)s stock had its buy rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday...
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on eFFECTOR Therapeutics (EFTR Research Report). The associated price ta...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the Company ), a leader in the development of selective translation...